How to Help Your Patients Save Money on Xeljanz XR: A Provider's Guide to Savings Programs

Xeljanz XR (tofacitinib extended-release) has a retail price of approximately $8,700 per month — placing it firmly in the category of specialty biologics and advanced therapies that create significant financial stress for patients. Treatment interruptions due to cost directly worsen disease outcomes for RA, PsA, AS, and UC patients. This guide outlines every savings pathway available to your patients in 2026 and how to efficiently connect them to the right program.

Understanding the Cost Landscape for Xeljanz XR in 2026

As of 2026, the full retail cash price for a 30-day supply of Xeljanz XR 11 mg is approximately $8,712. With GoodRx coupons, that drops to approximately $3,200 at select pharmacies — still prohibitively expensive for most cash-paying patients.

Commercially insured patients with access to the Pfizer copay card can pay as little as $0 per month. Medicare patients face a $2,000 annual out-of-pocket cap under Part D (effective 2025). Uninsured or government-underinsured patients may qualify for free medication through the Pfizer RxPathways PAP. Understanding which category each patient falls into is the first step.

Program 1: Pfizer XELJANZ Co-Pay Savings Program (Commercially Insured)

This is the primary affordability program for commercially insured patients. Key details:

Benefit: Reduces monthly out-of-pocket cost to as little as $0; maximum savings of up to $15,000 per calendar year

Eligibility: Commercially insured patients only. NOT available for Medicare, Medicaid, TRICARE, VA, or any federal/state healthcare programs.

Coverage: Applies to all Xeljanz formulations (XR, tablets, oral solution)

Enrollment: Call XELSOURCE at 1-844-935-5269 or visit xeljanz.com/savings-and-support. Enroll at the time of prescribing to avoid delays.

Expiration: Program expires 12/31/2026; ensure patients re-enroll if the program is renewed annually.

Important: Be aware of copay accumulator adjustors on some employer plans. These plans do not count manufacturer copay card payments toward the patient's deductible or out-of-pocket maximum. This can leave patients facing large cost responsibilities later in the year. Ask your specialty pharmacy or XELSOURCE if the patient's plan uses a copay accumulator.

Program 2: Pfizer RxPathways Patient Assistance Program (Uninsured/Government Underinsured)

For patients without commercial insurance — including those on Medicare without adequate Part D coverage — the Pfizer RxPathways PAP provides Xeljanz XR at no cost to eligible patients.

Income guidelines: Approximately $40,000/year for individuals, $60,000/year for couples, up to $100,000 for larger families

Application: Physician signature required. Apply at pfizerrxpathways.com or call 1-877-744-5675. Submission by mail or fax.

Note: Commercially insured patients are not eligible; the program is intended as a safety net for patients without coverage.

Program 3: New Patient Free Trial (Bridge Supply)

New patients who have not previously used Xeljanz/Xeljanz XR may receive a one-time free 30-day supply while prior authorization is processed. This is invaluable for preventing treatment gaps at initiation.

Voucher expires 12/31/2026; available at participating pharmacies or through XELSOURCE

Patient must present original voucher + valid prescription; cannot have current Xeljanz use

Cannot be submitted for Medicare/Medicaid reimbursement

Medicare Part D: What Xeljanz XR Patients Face in 2026

As of 2025, the Inflation Reduction Act caps Medicare Part D beneficiaries' annual out-of-pocket spending at $2,000 per year for covered drugs. This is a significant improvement for Xeljanz XR patients on Medicare who previously faced catastrophic cost phases.

For patients who qualify for Extra Help (Low Income Subsidy), copays for specialty drugs like Xeljanz XR may be minimal or zero. Ensure your Medicare patients are screened for Extra Help eligibility — it can be applied for through Social Security.

Formulary and Prior Auth Strategies to Lower Patient Cost

Beyond manufacturer programs, prescribers can influence patient cost through smart prescribing and appeals strategies:

Check formulary tier before prescribing: Xeljanz XR is typically Tier 4 or 5 (specialty). If the patient's plan has Rinvoq (upadacitinib) or generic tofacitinib at a lower tier, that may be the more accessible option.

Consider generic tofacitinib IR for cost-sensitive patients: Generic tofacitinib 5 mg twice daily has been available since June 2021 and is significantly less expensive. Generic XR (Ajanta Pharma) was approved in August 2025. If the patient can tolerate twice-daily dosing, this may be covered at a lower tier.

File PA exceptions for clinical necessity: When step therapy requirements are clinically inappropriate, exception requests with strong documentation can result in approval at the preferred copay tier, skipping step requirements.

90-day supply: Encourage patients with stable dosing to switch to 90-day mail-order supplies, which often have lower per-fill costs and reduce the number of specialty pharmacy transactions.

Recommended Workflow for Financial Assistance at Initiation

Identify insurance type (commercial, Medicare, Medicaid, uninsured)

Enroll in XELSOURCE at time of prescribing (1-844-935-5269) — they'll verify benefits, initiate PA, and identify savings programs automatically

Issue a free trial voucher for new commercially insured patients to bridge the PA period

For uninsured/underinsured patients: complete RxPathways PAP paperwork at the visit if possible

For Medicare patients: screen for Extra Help eligibility; confirm $2,000 cap applies to their Part D plan

For support helping patients locate the pharmacy that can fill their Xeljanz XR, refer them to medfinder for providers — we call pharmacies on their behalf to find which ones have it in stock and can fill the prescription.

See also our clinical overview: Xeljanz XR access issues: What providers need to know in 2026.